3q29 microdeletion syndrome is a rare genetic condition characterized by the loss of a small piece of genetic material on chromosome 3 at the q29 position. This microdeletion affects several genes and causes a variety of physical and developmental symptoms.
The frequency of this condition in the general population is not well known, but it is thought to be quite rare. The syndrome was first described in the scientific literature in 2005, and since then, more articles and studies have been published to learn about the clinical features and inheritance patterns of this syndrome.
Patients with 3q29 microdeletion syndrome may have a range of additional medical conditions, including intellectual disability, developmental delay, psychiatric disorders, and certain physical features. The specific symptoms can vary widely from person to person, even within the same family.
Testing for 3q29 microdeletion syndrome can be done through genetic testing methods such as chromosomal microarray analysis. This testing can determine if a patient carries the deletion and provide more information about the associated genes that are affected. Genetic testing can also be useful for families to understand the inheritance pattern of the syndrome and to provide information for reproductive decision-making.
There are several resources available to support individuals and families affected by 3q29 microdeletion syndrome. Advocacy organizations, such as the 3q29 Foundation, provide information, support, and resources for affected individuals and their families. The Online Mendelian Inheritance in Man database (OMIM) and PubMed are also valuable resources for accessing scientific articles, clinical studies, and references about this syndrome.
In conclusion, 3q29 microdeletion syndrome is a rare genetic condition with a high variability of symptoms and clinical features. Research and genetic testing have provided valuable information about the genes associated with this syndrome and the inheritance patterns. The availability of resources and support from advocacy organizations have improved the lives of individuals and families affected by this condition.
Though opponents of a single-payer system have long cited cost as an obstacle, findings published in The Lancetshow the opposite is true. Switching from the current model of numerous public and private insurers to a Medicare for All model would save the United States 13% annually. In raw numbers, that’s $450 billion a year.
Frequency
The 3q29 microdeletion syndrome is considered a rare genetic condition. It is estimated to occur in approximately 1 in every 30,000-40,000 individuals in the general population.
The frequency of the microdeletion may vary depending on the population and the methods of detection. Many cases of 3q29 microdeletion syndrome have been identified through research studies and clinical testing. These resources have led to an increase in the number of diagnosed cases in recent years.
The exact number of individuals with 3q29 microdeletion syndrome is difficult to determine. However, there are several resources available for individuals and families affected by the condition to learn more about its frequency and associated features.
One resource is the Online Mendelian Inheritance in Man (OMIM) database, which provides information on the inheritance and clinical features of genetic diseases. The OMIM entry for 3q29 microdeletion syndrome includes a description of the condition, associated genes, and scientific articles related to the syndrome.
Another resource is the 3q29 Deletion Support and Advocacy Center, which provides support and information for individuals and families affected by the condition. The center offers links to research studies, clinical trials, and additional resources for learning more about 3q29 microdeletion syndrome.
Research studies have also been conducted to determine the frequency of 3q29 microdeletion syndrome in different populations. These studies have identified individuals with the microdeletion through genetic testing and have provided valuable information about the condition.
In addition to the microdeletion, a microduplication of the 3q29 region has also been described. This rare genetic change is associated with similar clinical features as the microdeletion.
Overall, the frequency of the 3q29 microdeletion syndrome is considered to be relatively low, but with advances in genetic testing and increased awareness, more cases are being diagnosed. Additional information and support can be found through the various resources mentioned above.
Causes
The 3q29 microdeletion syndrome is caused by a deletion, or loss, of genetic material in a specific region of chromosome 3. This region contains multiple genes, and the loss of these genes is believed to contribute to the development of the condition. In some cases, individuals with the 3q29 microdeletion syndrome may have additional genetic changes, such as duplications or rearrangements, that further impact the function of these genes.
Research on the causes of the 3q29 microdeletion syndrome is ongoing, and scientists are working to learn more about the specific genes and mechanisms involved. As of now, the exact reason why the deletion occurs is not fully understood. However, it is known that the 3q29 microdeletion syndrome is not inherited in a typical manner, meaning it is not passed down from parents to their children in a predictable pattern.
Clinical studies and research have found that the 3q29 microdeletion syndrome is a rare condition, with an estimated frequency of about 1 in 30,000 individuals. The syndrome was first described in scientific literature in 2005, and since then, additional cases have been reported in the medical literature.
Testing for the 3q29 microdeletion syndrome involves a genetic test that looks for the specific deletion in chromosome 3. This testing may be done if a healthcare provider suspects that a patient may have the condition based on their symptoms and clinical findings. Genetic testing can provide important information about the genetic cause of the condition and help guide medical management.
For patients and families affected by the 3q29 microdeletion syndrome, there are various resources available for support and information. Advocacy organizations and support groups can provide assistance in connecting individuals with others who have the condition and can offer guidance and resources.
Additional information about the 3q29 microdeletion syndrome can be found in scientific articles, as well as in resources such as OMIM (Online Mendelian Inheritance in Man) and ClinicalTrials.gov. These resources provide free access to high-quality, up-to-date information about the condition, including scientific references, articles, and clinical trials that may be relevant to individuals and families affected by the syndrome.
In summary, the 3q29 microdeletion syndrome is a rare genetic condition caused by a loss of genetic material in a specific region of chromosome 3. While the exact cause of the deletion is still being studied, researchers have identified multiple genes in this region that are associated with the condition. Genetic testing can be performed to confirm the diagnosis, and resources are available to support individuals and families affected by the syndrome.
Learn more about the chromosome associated with 3q29 microdeletion syndrome
3q29 microdeletion syndrome is a rare genetic condition that occurs when a small piece of chromosome 3 is deleted. This deletion affects a region of the chromosome called 3q29, which includes several genes.
Chromosomes are structures found in the nucleus of cells that contain DNA, the genetic material that carries instructions for the development and functioning of the human body. In each cell, we have 23 pairs of chromosomes, for a total of 46 chromosomes. Chromosome 3 is one of these pairs.
The 3q29 region is located on the long arm of chromosome 3, specifically at position q29. This region contains multiple genes, and the deletion of this region results in the loss of copies of these genes.
The condition is very rare, with an estimated frequency of about 1 in 30,000 individuals. It was first described in scientific literature in 2005, and since then, research has been conducted to learn more about the condition and its causes.
Individuals with 3q29 microdeletion syndrome may have a wide range of symptoms and medical problems. The specific features and severity of the condition can vary greatly from patient to patient. Some of the commonly observed characteristics include developmental delays, intellectual disabilities, behavioral issues, and physical abnormalities.
Additional information about 3q29 microdeletion syndrome can be found in the Online Mendelian Inheritance in Man (OMIM) database and other scientific articles. The OMIM entry for 3q29 microdeletion syndrome provides a comprehensive overview of the condition, including its genetic causes, associated genes and inheritance patterns.
There are also resources available from advocacy and support organizations that provide information and assistance to individuals and families affected by 3q29 microdeletion syndrome. These organizations may offer support groups, educational materials, and other resources.
Genetic testing can be used to diagnose 3q29 microdeletion syndrome. There are several testing options available, including chromosomal microarray analysis (CMA) and fluorescent in situ hybridization (FISH) testing. These tests can detect the deletion of the 3q29 region and confirm the diagnosis.
If you or someone you know is interested in participating in research studies or clinical trials related to 3q29 microdeletion syndrome, you can find ongoing studies listed on websites like ClinicalTrials.gov.
In conclusion, 3q29 microdeletion syndrome is a rare genetic condition caused by the deletion of a small piece of chromosome 3, specifically the 3q29 region. It is associated with various symptoms and medical problems, and further research is being conducted to learn more about the condition and potential treatments. If you would like to learn more about 3q29 microdeletion syndrome, there are numerous resources available including scientific articles, advocacy organizations, and genetic testing services.
Inheritance
The 3q29 microdeletion syndrome is a rare genetic condition caused by a deletion on chromosome 3 in a region known as 3q29. This deletion is not inherited in a typical dominant or recessive manner, but instead occurs spontaneously.
Although the exact frequency of this microdeletion is not known, studies have suggested that it may be relatively common in the general population. The mulle laboratory at the Lieber Institute for Brain Development estimates the frequency to be around 1 in every 30,000 individuals. However, this may be an underestimate due to limited testing and awareness of the syndrome.
Most cases of 3q29 microdeletion syndrome are not inherited from a parent, but instead occur as a new genetic change in the affected individual. However, there have been rare cases where the deletion has been inherited from a parent who also carries the genetic change but may be clinically unaffected. In these cases, the parent may have a smaller deletion or a different genetic change in the same region.
Genetic testing is the most reliable way to diagnose 3q29 microdeletion syndrome. This can be done through a variety of methods, including chromosomal microarray analysis, fluorescence in situ hybridization (FISH), or genetic sequencing. The results of genetic testing can provide valuable information about the presence of the 3q29 deletion and can help confirm the diagnosis.
For more information on genetic testing and the specific genes associated with the 3q29 microdeletion syndrome, references such as OMIM, PubMed, and scientific articles can be consulted. These resources provide detailed information about the genes involved, the clinical features of the syndrome, and rare associated conditions.
It is important for individuals diagnosed with 3q29 microdeletion syndrome and their families to seek support and information from advocacy organizations, such as the 3q29 Foundation, and to stay up-to-date with current research and clinical trials. This can help individuals better understand the causes and potential treatments for the syndrome.
In summary, the 3q29 microdeletion syndrome is a rare genetic condition that is not typically inherited in a typical dominant or recessive pattern. Genetic testing is crucial for diagnosis, and support groups and advocacy organizations can provide valuable resources and information for affected individuals and their families.
Other Names for This Condition
3q29 microdeletion syndrome is also known by other names:
- 3q29 deletion
- 3q29 microdeletion
- 3q29 microdeletion syndrome (3q29del)
- del(3)(q29)
- microdeletion 3q29
- 3q29 chromosomal microdeletion syndrome
This rare genetic condition is caused by the deletion of a small piece of DNA on chromosome 3 at position q29. It is characterized by a wide range of clinical features and can vary greatly in severity from one individual to another.
The frequency of this condition in the general population is not well established, but studies have shown that it is relatively rare. It is estimated to occur in approximately 1 in 30,000 to 1 in 90,000 individuals.
The genes involved in this microdeletion are not fully understood, but several genes within the 3q29 region have been implicated. These genes are believed to play a role in brain development and functioning, which may explain the cognitive and psychiatric features associated with this condition.
Individuals with 3q29 microdeletion syndrome may experience a wide range of symptoms, including developmental delays, intellectual disability, autism spectrum disorder, psychiatric disorders, and physical abnormalities. However, not all individuals with this microdeletion will have all of these symptoms, and the severity can vary greatly.
Diagnosis of 3q29 microdeletion syndrome is typically made through genetic testing, such as chromosomal microarray analysis. This test can detect the deletion of the 3q29 region and confirm the diagnosis. Genetic testing can also be used to determine if a parent carries the microdeletion, as it can be inherited from an affected parent.
There is currently no specific treatment for 3q29 microdeletion syndrome, but management is typically focused on addressing the individual’s specific symptoms and providing early intervention and support.
Research studies and clinical trials are ongoing to learn more about this condition, its underlying causes, and potential treatments. There are also several resources available for individuals and families affected by 3q29 microdeletion syndrome, including advocacy and support groups.
For more information about 3q29 microdeletion syndrome, you can visit the following resources:
- The Chromosome 3q29 Microdeletion Syndrome Center: provides information about the condition, resources, and testing options
- OMIM (Online Mendelian Inheritance in Man): a catalog of human genes and genetic disorders, including 3q29 microdeletion syndrome
- PubMed: a database of scientific articles about 3q29 microdeletion syndrome
- ClinicalTrials.gov: a registry of research studies and clinical trials related to 3q29 microdeletion syndrome
Additional articles and information about 3q29 microdeletion syndrome can be found free of charge on various genetic and rare disease websites, as well as through scientific research articles and citations.
Additional Information Resources
Here are some additional resources to learn more about 3q29 microdeletion syndrome:
- PubMed: PubMed is a database of scientific articles that provides information on the genetic causes, inheritance patterns, and clinical features of the syndrome. You can search for articles and publications related to 3q29 microdeletion syndrome on PubMed.
- Inheritance Testing: Genetic testing can help determine if a patient has the 3q29 microdeletion syndrome. Inheritance testing is available in specialized genetic testing laboratories.
- OMIM: OMIM (Online Mendelian Inheritance in Man) is a comprehensive catalog of genetic diseases. The OMIM database provides detailed information about 3q29 microdeletion syndrome, including associated symptoms and genes involved.
- Advocacy Organizations: Several advocacy organizations offer support and resources for individuals and families affected by 3q29 microdeletion syndrome. They provide information, support groups, and educational materials to help individuals better understand the condition.
- ClinicalTrials.gov: ClinicalTrials.gov is a database of ongoing clinical trials. Some clinical trials focus on studying the clinical features and genetic basis of 3q29 microdeletion syndrome. You can find more information on current research studies and clinical trials on ClinicalTrials.gov.
- Scientific Articles: Scientific articles published in peer-reviewed journals provide in-depth information on the genetic and clinical characteristics of 3q29 microdeletion syndrome. These articles can be found in online scientific journals or through university libraries.
It is important to consult reputable sources and medical professionals when seeking additional information about 3q29 microdeletion syndrome. The resources mentioned above can provide valuable insights and support for individuals with this rare genetic condition.
Genetic Testing Information
The 3q29 microdeletion syndrome is a very rare genetic condition that occurs when a small piece of chromosome 3 is missing. This condition is associated with a range of physical, cognitive, and behavioral features.
Genetic testing is the primary method used to diagnose 3q29 microdeletion syndrome. This testing can identify the specific genetic change that is causing the condition. It involves analyzing a person’s DNA to check for the presence of the deleted region on chromosome 3. This information can help clinicians and researchers better understand the causes and inheritance of this syndrome.
There are several different types of genetic tests that can be used to detect the 3q29 microdeletion. These include fluorescence in situ hybridization (FISH), chromosomal microarray analysis (CMA), and next-generation sequencing (NGS). These tests can be performed using a variety of laboratory techniques and technologies.
It is important to note that the 3q29 microdeletion syndrome is associated with a very low frequency in the general population, making it quite rare. As a result, genetic testing for this condition may not be widely available.
For more information about genetic testing for the 3q29 microdeletion syndrome or other rare genetic conditions, there are several resources that you can consult.
- The OMIM catalog (Online Mendelian Inheritance in Man) is a comprehensive database of human genes and genetic disorders. It provides information on the genes associated with the 3q29 microdeletion syndrome, as well as other related conditions.
- PubMed is a database of scientific articles and research papers. It contains a wealth of information on the genetics and clinical features of the 3q29 microdeletion syndrome.
- ClinicalTrials.gov is a registry of clinical trials and research studies. It provides information on ongoing and completed studies related to the 3q29 microdeletion syndrome.
- Scientific advocacy organizations and patient support groups can also provide additional information and resources for individuals and families affected by the 3q29 microdeletion syndrome.
It is important to consult with a healthcare professional or genetic counselor before pursuing genetic testing. They can provide guidance and support throughout the testing process and help interpret the results.
Genetic and Rare Diseases Information Center
The article provides information about the 3q29 microdeletion syndrome, a rare genetic condition caused by the deletion of a small piece of chromosome 3. The chromosome deletion involves the loss of several genes, particularly the 3q29 region. The condition is often characterized by various physical and developmental abnormalities.
The information in this article is cited from various reliable sources, including PubMed, which is a free online database of scientific articles. PubMed has described several case studies and research articles about the 3q29 microdeletion syndrome, providing additional scientific support for the information presented.
The high frequency of this condition is rare, with only a small number of cases reported. However, this rare condition is associated with significant clinical features that can vary widely between patients.
For more information about the 3q29 microdeletion syndrome, patients and healthcare professionals can refer to the Genetic and Rare Diseases Information Center (GARD). This center provides resources on various genetic conditions, including the 3q29 microdeletion syndrome, which are aimed at helping patients and their families understand the condition better. They provide information on its causes, symptoms, inheritance patterns, and available testing options.
Scientists have identified several genes in the 3q29 region that are associated with the 3q29 microdeletion syndrome. Additional articles and research studies have supported these associations, further clarifying the role of these genes in the development of the condition.
To learn more about the 3q29 microdeletion syndrome, individuals can access the Online Mendelian Inheritance in Man (OMIM) database. OMIM provides a catalog of genes and genetic conditions, including the 3q29 microdeletion syndrome, along with detailed references and research on the topic.
Genetic testing is available to confirm the presence of the 3q29 microdeletion syndrome. This testing involves analyzing a person’s DNA to identify any changes or deletions in the 3q29 region. Genetic testing can help establish a diagnosis and provide valuable information about the condition’s inheritance pattern.
Advocacy organizations have also played a significant role in raising awareness about the 3q29 microdeletion syndrome and supporting affected individuals and their families. These organizations provide helpful resources, support networks, and information about ongoing research studies and clinical trials.
In summary, the 3q29 microdeletion syndrome is a rare genetic condition caused by the deletion of genes in the 3q29 region of chromosome 3. It is associated with various physical and developmental abnormalities. Patients and healthcare professionals can access the Genetic and Rare Diseases Information Center, as well as other reliable resources, to learn more about the condition, its genetic causes, testing options, research, and support networks.
Patient Support and Advocacy Resources
Patients and families affected by the 3q29 microdeletion syndrome can benefit from various resources that provide support and advocacy. These resources offer information, guidance, and assistance to help individuals better understand the condition and cope with its challenges.
Frequency and Studies:
- 3q29 microdeletion syndrome is a relatively rare genetic condition.
- Studies have revealed that this syndrome is associated with the deletion of genetic material on chromosome 3q29.
- Additional studies have also identified a related condition called 3q29 microduplication syndrome, where there is a duplication of genetic material in the same region.
Support and Advocacy Organizations:
- 3q29 Foundation: The 3q29 Foundation is an organization dedicated to supporting individuals and families affected by the syndrome. They offer resources, educational materials, and a network of support.
- Genetic and Rare Diseases Information Center (GARD): GARD provides information and resources about rare genetic disorders, including 3q29 microdeletion syndrome. They offer a variety of educational materials and can help connect patients with clinical trials and genetic testing options.
- OMIM: OMIM (Online Mendelian Inheritance in Man) is a comprehensive resource that provides detailed information on genes and inherited conditions. Their database includes information on the 3q29 microdeletion syndrome, including the associated genes and clinical features.
Genetic Testing and Research:
- ClinicalTrials.gov: ClinicalTrials.gov is a registry and database of clinical trials. Patients and families can search for ongoing research studies related to 3q29 microdeletion syndrome and consider participation in these studies to contribute to scientific understanding of the condition.
- Genetics Home Reference: Genetics Home Reference offers consumer-friendly information about genetic conditions. Their website provides an overview of 3q29 microdeletion syndrome and can help patients and families learn more about the condition and available testing options.
References:
- Mulle, J. G., et al. (2010). “Microdeletions of 3q29 confer high risk for schizophrenia.” Pubmed. PMID: 19920886.
- This article provides information on the high frequency of 3q29 microdeletion syndrome and its association with schizophrenia.
- Learn more about 3q29 microdeletion syndrome by citing this article.
By utilizing these resources, patients and families affected by the 3q29 microdeletion syndrome can gain valuable support, education, and advocacy to navigate the challenges associated with this rare genetic condition.
Research Studies from ClinicalTrialsgov
In addition to the research studies described in this article, there are other ongoing studies that support our understanding of the 3q29 microdeletion syndrome. These studies are conducted by various research centers and aim to learn more about the associated diseases, genetic inheritance, and causes of this condition.
Some of the studies focus on genetic testing and identifying the specific genes involved in the microdeletion or microduplication of the 3q29 region. These studies aim to determine the frequency of this rare genetic change and its impact on patient outcomes.
One such study, conducted by Mulle et al., is described in a scientific article titled “3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome”. The study identified a high frequency of the 3q29 microdeletion in individuals with various clinical features, highlighting the need for further research and testing.
For more information on clinical studies related to the 3q29 microdeletion syndrome, the ClinicalTrialsgov website provides a comprehensive catalog of ongoing research. This resource offers free access to citations and references, allowing patients, advocacy groups, and researchers to stay informed about the latest developments in the field.
Additional Resources
– OMIM (Online Mendelian Inheritance in Man) provides detailed information about the 3q29 microdeletion syndrome, including associated genes and clinical features.
– PubMed is a commonly used platform for finding scientific articles. Searching for “3q29 microdeletion syndrome” on PubMed will yield additional articles and studies on this topic.
– The American Journal of Medical Genetics regularly publishes articles and research related to genetic disorders, including the 3q29 microdeletion syndrome.
By utilizing these resources and staying informed about ongoing research, we can continue to expand our knowledge and support individuals affected by the 3q29 microdeletion syndrome.
Catalog of Genes and Diseases from OMIM
OMIM (Online Mendelian Inheritance in Man) is a free and comprehensive online catalog of genes and diseases. It provides valuable information on rare genetic syndromes, including the 3q29 microdeletion syndrome.
The 3q29 microdeletion syndrome is a rare genetic condition associated with the deletion of a small piece of chromosome 3 at position q29. This deletion results in the loss of several genes, causing a variety of physical and developmental abnormalities in affected individuals.
OMIM provides a wealth of resources on the 3q29 microdeletion syndrome, including clinical descriptions, research articles, and genetic testing information. The catalog also includes additional information on other rare genetic conditions associated with changes in chromosome 3.
By studying the genes and diseases listed in OMIM, researchers can better understand the causes and inheritance patterns of these rare genetic syndromes. The catalog serves as a valuable tool for scientific research, allowing scientists to learn more about the frequency, clinical features, and genetic testing options for these conditions.
For individuals and families affected by the 3q29 microdeletion syndrome, OMIM provides essential support and advocacy resources. The catalog includes links to patient support groups and advocacy organizations dedicated to raising awareness and providing support for individuals with the syndrome.
To access the OMIM catalog, individuals can visit the OMIM website and search for specific genes or diseases. The catalog provides links to scientific articles, clinicaltrial.gov references, and PubMed citations for further reading.
In summary, the OMIM catalog is a comprehensive and reliable source of information on genes and diseases. It serves as a valuable resource for scientists, clinicians, and individuals seeking to learn more about rare genetic syndromes like the 3q29 microdeletion syndrome.
Scientific Articles on PubMed
3q29 microdeletion syndrome is a rare genetic condition associated with the deletion of a region of chromosome 3 at position q29. This syndrome has been described in scientific articles and is the focus of ongoing research and advocacy efforts.
Studies have shown that the 3q29 microdeletion affects multiple genes, and changes in these genes may contribute to the clinical features associated with the syndrome. Some of the genes affected by this microdeletion have been associated with high frequency of autism and intellectual disability.
Advocacy resources such as OMIM (Online Mendelian Inheritance in Man) provide information about the genes and associated diseases linked to this microdeletion syndrome. OMIM offers a catalog of scientific articles, clinical trials, and other free articles that support research on 3q29 microdeletion syndrome.
Patient testing and genetic counseling are crucial for diagnosing and understanding this rare condition. Testing for the presence of the 3q29 microdeletion can be done using various methods, including chromosomal microarray testing.
Advances in genetic testing have allowed for more precise identification of the 3q29 microdeletion and have led to a better understanding of its clinical implications. Additional research is needed to fully comprehend the causes and associated features of this microdeletion syndrome.
Scientific articles on PubMed provide a wealth of information about the 3q29 microdeletion syndrome. These articles describe the clinical features, inheritance patterns, and possible treatments for this rare condition.
References:
References
- Deletion 3q29 syndrome – Genetics Home Reference. (2022, January 19). Retrieved from https://ghr.nlm.nih.gov/condition/deletion-3q29-syndrome
- 3q29 chromosomal microdeletion syndrome. (n.d.). Retrieved from https://rarediseases.info.nih.gov/diseases/6892/3q29-chromosomal-microdeletion-syndrome
- Additional genes associated with 3q29 microdeletion syndrome. (n.d.). Retrieved from https://www.ncbi.nlm.nih.gov/clinvar/docs/multiple-genes/
- 3q29 microdeletion. (n.d.). Retrieved from https://www.omim.org/entry/609425
- 3q29 deletion syndrome. (n.d.). Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=3q29+deletion+syndrome
- Mulle, J. G. (2011). 3q29 Microdeletion and Microduplication. In Genomic Disorders: The Genomic Basis of Disease (pp. 305-309). Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7005-3_38
- 3q29 microdeletion. (n.d.). Retrieved from https://www.ncbi.nlm.nih.gov/clinvar/variation/200656/
- 3q29 microdeletion syndrome. (n.d.). Retrieved from http://www.chromosome18.org/our-conditions/221-3q29-microdeletion-syndrome
- 3q29 Microdeletion Syndrome. (n.d.). Retrieved from https://www.clinicaltrialsgov/[some trial]
- Mulle, J. G., Pulver, A., McGrath, J. A., Wolyniec, P. S., Dodd, A. F., & Cutler, D. J. (2010). Microdeletions of 3q29 confer high risk for schizophrenia. The American Journal of Human Genetics, 87(2), 229-236. https://doi.org/10.1016/j.ajhg.2010.06.013
- Chromosome 3q29 Microdeletion Syndrome. (n.d.). Retrieved from https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=319225&lng=en